On Friday, October 10th investigators will report clinical trial results from the Prevention of Retained Blood Outcomes with Active Clearance Technology (PROACT) assessing the use of PleuraFlow to reduce Retained Blood Complications after Cardiac Surgery at FACTS-Care CVT 2014 in Washington, D.C. This is one of the largest studies to assess outcomes with Active Clearance Technology to reduce complications after heart surgery.
The post Mark your calendar! appeared first on ClearFlow.
Washington, DC.—October 10, 2014—ClearFlow Inc., a medical device company based in Anaheim, CA, today announced positive results from the Prevention of Retained Blood Outcomes Using Active Clearance Technology trial, (PRO-ACT), a clinical study evaluating the use of PleuraFlow® Active Clearance Technology™ System to prevent retained blood complications. The PleuraFlow System enables caregivers to actively keep chest drainage tubes clear of clot in the early hours after heart surgery. The PRO-ACT studied the efficacy of a protocol for actively clearing chest tubes of clotted blood to prevent retained blood complications. “Chest tube clogging is known to occur in over one-third of heart surgery patients in the early hours after heart surgery, and nearly one in five
The post ClearFlow announces positive clinical trial results for the reduction of hospital complications after heart surgery appeared first on ClearFlow.
WAYNE, N.J., Jan. 23, 2015 /PRNewswire/ — Maquet Medical Systems USA announced today an exclusive US distribution agreement with ClearFlow, Inc. for its innovative PleuraFlow® Active Clearance Technology® (ACT™) System. The PleuraFlow System enables caregivers to actively keep chest drainage tubes clear of clot in the early hours after heart surgery. Maquet’s sales representatives in the United States will begin selling PleuraFlow ACT during the first quarter of 2015. PleuraFlow ACT received 510(k) regulatory clearance from the U.S. Food and Drug Administration in December 2010. In October 2014, ClearFlow announced positive results from the Prevention of Retained Blood Outcomes Using Active Clearance Technology trial, (PRO-ACT), a clinical study evaluating the
The post Maquet Medical Systems USA Announces Exclusive US Distribution Agreement with ClearFlow for PleuraFlow® Active Clearance Technology® System appeared first on ClearFlow.
Groundbreaking Device Designed to Prevent Retained Blood Syndrome Draws Crowds in San Diego Anaheim, CA – January 26, 2015—ClearFlow Inc., a medical device company based in Anaheim, CA, is currently exhibiting its innovative PleuraFlow® Active Clearance Technology® System at the Society of Thoracic Surgeons (STS) 51st Annual Meeting in San Diego. PleuraFlow will continue to be displayed at ClearFlow’s booth (#636) at STS today and tomorrow. ClearFlow’s PleuraFlow System uses a first of its kind technology to enable caregivers to proactively keep chest drainage tubes clear of blood clotting in the early hours after heart surgery. PleuraFlow’s appearance and display at STS follows on the heels of Maquet Medical
The post ClearFlow Exhibits PleuraFlow System at Society of Thoracic Surgeons Annual Meeting appeared first on ClearFlow.
Anaheim, CA – March 2, 2015—ClearFlow Inc., a medical device company based in Anaheim, CA, is currently exhibiting its innovative PleuraFlow® Active Clearance Technology® System at the 34th annual Association of Physician Assistants in Cardiovascular Surgery (APACVS) meeting in Las Vegas. PleuraFlow will also be displayed at the Maquet Medical Systems USA booth through March 4th. Maquet is the exclusive distributor of ClearFlow’s PleuraFlow System in the USA. The PleuraFlow System uses a first of its kind technology to enable caregivers to proactively keep chest drainage tubes clear of blood clotting after heart surgery. “We understand the crucial role physician assistants play in the operating room during cardiovascular and cardiothoracic procedures,”
The post ClearFlow’s PleuraFlow System Exhibited at Association of Physician Assistants in Cardiovascular Surgery Meeting appeared first on ClearFlow.
Anaheim, CA – March 10, 2015—ClearFlow Inc., a medical device company based in Anaheim, CA, rallied its employees, their families and loved ones this past weekend in the name of heart health awareness for the American Heart Association’s 34th Annual Heart & Stroke Walk & 5K Run starting and finishing at Angel Stadium of Anaheim. Most of ClearFlow’s growing organization was represented at the event, with employees and their families getting involved to raise money for the good cause. “While our day to day efforts specifically focus on improving outcomes of cardiovascular and cardiothoracic procedures,” said ClearFlow President & CEO, Paul Molloy. “Heart health, improved quality of life and healthier
The post ClearFlow Employees Make a Stand For Heart Health At The American Heart Association’s Annual Heart & Stroke Walk & 5K Run appeared first on ClearFlow.
Anaheim, CA – March 25, 2015—Cardiac anesthesia investigators from Germany presented data this week at the International Anesthesia Research Society’s (IARS) 2015 Annual Meeting and International Science Symposium in Honolulu, HI. Critical care specialists from Charité – Universitätsmedizin Berlin’s Department of Anesthesiology and Intensive Care Medicine presented clinical data from 6,909 patients. Results from the data revealed that more than 16% of the patients studied required surgical reinterventions to deal with complications related to Retained Blood Syndrome (RBS). Patients who required reinterventions were reported to have a statistically significant increase in mortality, longer ICU and hospital stays as well as higher incidence of hemodialysis and longer ventilator time, complicating their
The post Study Demonstrates Concern for Retained Blood Syndrome after Heart Surgery appeared first on ClearFlow.
Seattle, WA–April 27, 2015—A panel of distinguished heart surgeons from leading cardiac centers shared their experiences and strategies to optimize patient recovery after cardiothoracic surgery at a panel discussion in Seattle yesterday. Of emphasis was the ongoing challenge of high complication rates for patients struggling with postoperative acute, sub-acute and chronic complications after surgery due to inadequate drainage, known as Retained Blood Syndrome (RBS). ClearFlow, Inc., a medical device company based in Anaheim, CA, hosted the Symposium at the recent American Association of Thoracic Surgeons (AATS) meeting in Seattle, where its award-winning technology was on exhibit for over 2,400 cardiac surgeons and healthcare professionals. ClearFlow is the manufacturer of the innovative
The post Surgeons Discuss High Readmission Rates for Patients with Retained Blood Syndrome After Cardiac Surgery appeared first on ClearFlow.
Anaheim, CA – May 11, 2015— ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that cardiac critical care investigators presented data last week at the 62nd annual German Anesthesia Congress (DAC 2015) in Düsseldorf, Germany about outcomes in patients who develop Retained Blood Syndrome (RBS) from incomplete blood evacuation after cardiac surgery. Cardiac Anesthesia specialists from Charité University Hospital Berlin’s Department of Anesthesiology and Intensive Care Medicine reported data showing that patients who developed RBS took longer to wean from the ventilator after surgery, stayed in the ICU longer (increase of 10 days), had longer hospital lengths of stay and suffered increased mortality. The clinical data was obtained
The post Clinical Investigators at German Anesthesia Congress Report Increased Stays in ICU Related to Retained Blood Syndrome After Cardiac Surgery appeared first on ClearFlow.
Anaheim, CA – June 03, 2015— ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that the United States Food & Drug Administration (FDA) has granted expanded Indications for Use of the company’s patented PleuraFlow® Active Clearance Technology® System. The PleuraFlow System is a patented medical device that prevents chest drains from occluding with clot, which can lead to retained blood around the heart and lungs. The composite of drainage related complications that are detrimental to outcomes after cardiothoracic surgery and that may require early or late intervention to remediate are known as Retained Blood Syndrome (RBS). These clinical complications have significant economic consequences, namely higher costs
The post FDA Expands Label Indication for PleuraFlow to Reduce Retained Blood appeared first on ClearFlow.
ClearFlow Participates in Clinical Panel Presentations and Round Table at Conference Focused on Clinical Impact of Retained Blood Washington, DC – October 6, 2015—ClearFlow Inc., a medical device company based in Anaheim, CA, participated in a series of panel presentations related to the subject of chest tube patency standards to prevent Retained Blood Syndrome (RBS) following cardiothoracic surgery last Friday at the Cardiovascular-Thoracic (CVT) Critical Care Conference in Washington DC. Clinical cardiac surgery intensive care leaders from around the world gathered at the conference, organized by the Foundation for the Advancement of CardioThoracic Surgical Care (FACTS-Care) in Washington, DC. CVT Critical Care Conference is one of the premier settings for cardiac critical care exchange of ideas.
The post Unmet -Need for Chest Tube Patency Standards an Area of Focus at Cardiovascular-Thoracic (CVT) Critical Care Conference appeared first on ClearFlow.
Amsterdam, Netherlands – October 8, 2015—ClearFlow Inc., a medical device company based in Anaheim, California, USA, exhibited its innovative PleuraFlow® Active Clearance Technology® System at the 29th annual Association for Cardio-Thoracic Surgery (EACTS) meeting in Amsterdam this week. The EACTS Annual Meeting is the largest cardio-thoracic meeting in the world, a position it has maintained for over a decade, and this year’s event featured ClearFlow’s PleuraFlow technology for the first time. The PleuraFlow System uses a first of its kind technology to enable caregivers to proactively keep chest drainage tubes clear of blood clotting after heart surgery. Earlier this year, clinical investigators from Charité – Universitätsmedizin Berlin’s Department of Anesthesiology
The post ClearFlow’s PleuraFlow System Exhibited at European Association for Cardio-Thoracic Surgery Meeting appeared first on ClearFlow.
Groundbreaking Device Designed to Prevent Retained Blood Syndrome Draws Crowds in San Diego Anaheim, CA – January 26, 2015—ClearFlow Inc., a medical device company based in Anaheim, CA, is currently exhibiting its innovative PleuraFlow® Active Clearance Technology® System at the Society of Thoracic Surgeons (STS) 51st Annual Meeting in San Diego. PleuraFlow will continue to be displayed at ClearFlow’s booth (#636) at STS today and tomorrow. ClearFlow’s PleuraFlow System uses a first of its kind technology to enable caregivers to proactively keep chest drainage tubes clear of blood clotting in the early hours after heart surgery. PleuraFlow’s appearance and display at STS follows on the heels of Maquet Medical
The post ClearFlow Exhibits PleuraFlow System at Society of Thoracic Surgeons Annual Meeting appeared first on ClearFlow.
Anaheim, CA – March 2, 2015—ClearFlow Inc., a medical device company based in Anaheim, CA, is currently exhibiting its innovative PleuraFlow® Active Clearance Technology® System at the 34th annual Association of Physician Assistants in Cardiovascular Surgery (APACVS) meeting in Las Vegas. PleuraFlow will also be displayed at the Maquet Medical Systems USA booth through March 4th. Maquet is the exclusive distributor of ClearFlow’s PleuraFlow System in the USA. The PleuraFlow System uses a first of its kind technology to enable caregivers to proactively keep chest drainage tubes clear of blood clotting after heart surgery. “We understand the crucial role physician assistants play in the operating room during cardiovascular and cardiothoracic procedures,”
The post ClearFlow’s PleuraFlow System Exhibited at Association of Physician Assistants in Cardiovascular Surgery Meeting appeared first on ClearFlow.
Anaheim, CA – March 10, 2015—ClearFlow Inc., a medical device company based in Anaheim, CA, rallied its employees, their families and loved ones this past weekend in the name of heart health awareness for the American Heart Association’s 34th Annual Heart & Stroke Walk & 5K Run starting and finishing at Angel Stadium of Anaheim. Most of ClearFlow’s growing organization was represented at the event, with employees and their families getting involved to raise money for the good cause. “While our day to day efforts specifically focus on improving outcomes of cardiovascular and cardiothoracic procedures,” said ClearFlow President & CEO, Paul Molloy. “Heart health, improved quality of life and healthier
The post ClearFlow Employees Make a Stand For Heart Health At The American Heart Association’s Annual Heart & Stroke Walk & 5K Run appeared first on ClearFlow.
Anaheim, CA – March 9, 2016—ClearFlow Inc., a medical device company based in Anaheim, California, has announced the publication of significantly positive results in a study evaluating the company’s PleuraFlow® Active Clearance Technology® System. Data indicating a marked reduction in Retained Blood Syndrome (RBS) and Postoperative Atrial Fibrillation (POAF) among patients recovering from heart surgery was published in the March issue of the Journal of Thoracic and Cardiovascular Surgery. Data from the peer-reviewed paper, titled “Active Clearance of Chest Drainage Catheters Reduces Retained Blood” was originally presented in October, 2015 at the Cardiovascular-Thoracic (CVT) Critical Care annual conference, organized by the Foundation for the Advancement of CardioThoracic Surgical Care (FACTS-Care) organization in
The post Newly Published Study Confirms Reduction in Retained Blood and Postoperative Atrial Fibrillation After Heart Surgery with PleuraFlow Active Clearance Technology appeared first on ClearFlow.
Designation recognizes the development of new solutions that benefit the healthcare industry WAYNE, N.J., March 29, 2016 /PRNewswire/ — Getinge Group announced its Maquet V8 Catheter and Maquet PleuraFlow Active Clearance Technology System have received Innovative Technology designation from Novation, the leading healthcare services company that serves the more than 100,000 members and affiliates of VHA Inc., UHC, Children’s Hospital Association, and Provista. The designation was based on reviews of the V8 Catheter and the PleuraFlow System by hospital experts who attended Novation’s Innovative Technology Expo in November 2015. The annual event provides medical technology suppliers with the opportunity to demonstrate product and gain direct feedback from onsite clinical experts
The post Getinge Group Receives Innovative Technology Designation from Novation for the ClearFlow PleuraFlow® Active Clearance Technology® (ACT™) System appeared first on ClearFlow.
Anaheim, CA – March 30, 2016—Cardiac Surgeons at the Montreal Heart Institute have published a report featured in this month’s Annals of Thoracic Surgery detailing how active clearance of chest tubes in the ICU non surgically treated a life-threatening episode of pericardial tamponade in a patient recovering from heart surgery (Annals of Thoracic Surgery, 101: 1159-1163, 2016). Affiliated with Université de Montréal in Quebec, the Montreal Heart Institute is an ultra-specialized hospital center dedicated to care, research, teaching, prevention, rehabilitation and the assessment of new technologies in cardiology. All patients recovering from heart surgery require chest tubes to evacuate shed blood around the heart and lungs in the initial hours
The post PleuraFlow Relieves Life-Threatening Pericardial Tamponade by Active Clearance of Chest Tubes after Heart Surgery appeared first on ClearFlow.
— ClearFlow Executive Comments on Possible Solutions to Hospital Acquired Infections — Anaheim, CA – April 6, 2016—Cardiac anesthesia investigators from Germany presented data revealing the role retained blood plays in hospital acquired infections after heart surgery this week at the Society of Cardiovascular Anesthesiologists (SCA) 2016 Annual Meeting and Workshops in San Diego, CA. Critical care specialists from Charité – Universitätsmedizin Berlin’s Department of Anesthesiology and Intensive Care Medicine presented clinical data from 6,909 patients undergoing heart surgery. Results from the data revealed that more than 19% of the patients studied required surgical reinterventions to deal with complications related to Retained Blood Syndrome (RBS). Patients who required reinterventions were
The post Study Reveals Retained Blood as Common Culprit Leading to Acquired Infections After Heart Surgery appeared first on ClearFlow.
— ClearFlow Executives Comment on Need for New Protocols — Anaheim, CA – April 13, 2016—Clinical data presented at the Society of Cardiovascular Anesthesiologists (SCA) 2016 Annual Meeting and Workshops in San Diego last week indicated that Hospital Acquired Infections (HAI) are 75% more likely to occur in patients with interventions for Retained Blood Syndrome (RBS) after heart surgery than in patients who do not have RBS. All patients having heart surgery are required to have drainage catheters to remove shed blood from around the heart and lungs in the early hours of recovery following surgery. Evidence has shown that these drainage catheters have a high failure rate due to
The post New Data Indicates Patients with Retained Blood are 75% More Likely to Suffer from Hospital Acquired Infections After Heart Surgery appeared first on ClearFlow.
